Moderna Inc. and Merck & Co. have announced successful Phase 3 results for their combined personalized mRNA-based therapy against melanoma, leading to a substantial increase in Moderna’s stock value. On Wednesday, August 19, 2026, shares for Moderna surged significantly in pre-market trading following the news of this successful **Moderna trial** collaboration, which involved a novel treatment outperforming Merck’s Keytruda when used alone.
The INTerpath-001 study assessed intismeran autogene, an experimental individualized neoantigen-targeted mRNA therapy, in conjunction with Merck’s Keytruda. This combination was administered to patients with resected stage IIB-IV cutaneous melanoma who had not previously received systemic treatment. The trial successfully met its primary objective of recurrence-free survival, as well as a key secondary objective of distant metastasis-free survival.
Compared to Keytruda administered by itself, the combined treatment demonstrated statistically significant improvements in both measured outcomes for patients whose melanoma had been completely removed through surgery. Researchers noted that the trial did not identify any new safety concerns, with the safety profiles of both intismeran and Keytruda remaining consistent with observations from prior studies. Evaluation of other secondary objectives, including overall survival, is ongoing.
A Breakthrough in Personalized Cancer Treatment
These findings mark the first positive Phase 3 results for a personalized therapy targeting neoantigens and for an mRNA-based cancer treatment. The study also represents the first Phase 3 trial to show a clinically significant improvement when compared to Keytruda as an adjuvant therapy for patients with resected melanoma, as reported by Revista ADVFN. The combined regimen considerably extended the period during which patients remained free from melanoma recurrence, according to DiarioBitcoin.
The personalized mRNA injection is tailored to the specific set of mutations identified in each patient’s tumor, differing from a universal vaccine. This approach aims to train the immune system to recognize individual tumor mutations while leveraging Keytruda to enhance the body’s ability to attack cancer more effectively. The goal is to reduce the uncertainty faced by patients post-surgery and to help prevent the disease from spreading to distant parts of the body.
For patients, the period without relapse is a critical indicator, especially since most recurrences of melanoma, which accounts for the majority of skin cancer deaths, occur within two to three years following initial treatment and surgical removal. A therapy capable of extending this recurrence-free period could offer patients more time without signs of the disease, as highlighted by Dr. Jane Healy, Merck’s director of early oncology development.
Global Implications and Market Reaction
The market’s response underscored the significance of this clinical program. Moderna’s shares surged by over 90%, or approximately 100% according to DiarioBitcoin, in pre-market trading, while Merck’s stock rose more than 8%. The larger percentage increase for Moderna was partly due to its considerably smaller market capitalization at the start of the trading day. Analysts like Myles Minter from William Blair have upgraded Moderna’s stock, noting a clear path for the company to diversify its revenue beyond its COVID-19 business.
This development carries substantial global implications, offering a significant stride in the worldwide battle against melanoma, a particularly aggressive form of skin cancer. It validates the broader potential of mRNA technology beyond infectious diseases, signaling a potential paradigm shift in oncology. Such breakthroughs can influence global pharmaceutical investments, regulatory policies, and public health strategies, making personalized cancer treatments more accessible internationally.
Moderna and Merck intend to present these positive results at an upcoming international medical conference and will share the data with regulatory authorities for potential approval. The companies are also broadly exploring this therapeutic strategy, with nine additional Phase 2 and 3 clinical trials currently underway for various other tumor types, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma.
Moving forward, the focus will remain on the ongoing evaluation of other clinical outcomes, particularly overall survival data from the current trial. Future results from studies involving other cancer types will be crucial in fully assessing the long-term benefits and broader therapeutic reach of this personalized mRNA treatment approach, providing further insights into its potential impact on cancer care.
Image: Revista ADVFN
Sources consulted
- RFI: Moderna y Merck anuncian resultados positivos de una vacuna contra el cáncer de piel
- Revista ADVFN: Acciones de Moderna se disparan más de 90% tras éxito en ensayo fase 3 contra melanoma
- DiarioBitcoin: Moderna y Merck logran avance con vacuna personalizada contra el melanoma
Liora Sen is a health writer dedicated to wellness, medical research, and preventive care. She translates complex health topics into clear, reliable information that empowers readers to make better lifestyle and healthcare decisions. Her approach combines scientific awareness with everyday practicality.
